Together, these findings suggest that the LRP5/LIMA1–MYO5B signaling axis exerts its inhibitory effects on breast cancer bone metastasis via a multi-target, synergistic mechanism, directly restraining tumor cell invasion while simultaneously remodeling the immune and bone metabolic microenvironments. Here, LRP5 is linked to breast carcinoma.